Acacetin inhibits the proliferation of Hep G2 by blocking cell cycle progression and inducing apoptosis

Biochemical Pharmacology

Volumn 67, Issue 5, 2004, Pages 823-829

  Hsu, Ya Ling ^a   Kuo, Po Lin ^a   Lin, Chun Ching ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acacetin; Apoptosis; Cell cycle; Fas APO 1; FasL; p53

Indexed keywords

ACACETIN; FAS LIGAND; FLAVONOID; PROTEIN BAX; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIVER CARCINOMA; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLUBILITY; STATISTICAL SIGNIFICANCE;

EID: 1042275543     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.09.042     Document Type: Article

References (25)

1. Seow T.K., Liang R.C., Leow C.K., Chung M.C. Hepatocellular carcinoma: from bedside to proteomics. Proteomics. 1:2001;1249-1263.
2. Kern M.A., Breuhahn K., Schirmacher P. Molecular pathogenesis of human hepatocellular carcinoma. Adv. Cancer Res. 86:2002;67-112.
3. Hengartner M.O. The biochemistry of apoptosis. Nature. 407:2000;770-776.
4. Brown J.M., Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 59:1999;1391-1399.
5. Cody V. Crystal and molecular structures of flavonoids. Prog. Clin. Biol. Res. 280:1988;29-44.
6. Hertog M.G., Hollman P.C., Katan M.B., Kromhout D. Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer. 20:1993;21-29.
7. 4-induced microsomal lipid peroxidation. Experientia. 47:1991;195-199.
8. Liao Y.H., Houghton P.J., Hoult J.R. Novel and known constituents from Buddleja species and their activity against leukocyte eicosanoid generation. J. Nat. Prod. 62:1999;1241-1245.
9. Kraft C., Jenett-Siems K., Siems K., Jakupovic J., Mavi S., Bienzle U., Eich E. In vitro antiplasmodial evaluation of medicinal plants from Zimbabwe. Phytother. Res. 17:2003;123-128.
10. Kawaii S., Tomono Y., Katase E., Ogawa K., Yano M. Effect of citrus flavonoids on HL-60 cell differentiation. Anticancer Res. 19:1999;1261-1269.
11. Zhang K., Yang E.B., Tang W.Y., Wong K.P., Mack P. Inhibition of glutathione reductase by plant polyphenols. Biochem. Pharmacol. 54:1997;1047-1053.
12. Doostdar H., Burke M.D., Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology. 144:2000;31-38.
13. Boege F., Straub T., Kehr A., Boesenberg C., Christiansen K., Andersen A., Jakob F., Kohrle J. Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I. J. Biol. Chem. 271:1996;2262-2270.
14. Kikuchi S., Hiraide H., Tamakuma S., Yamamoto M. Expression of wild-type p53 tumor suppressor gene and its possible involvement in the apoptosis of thyroid tumors. Jpn. J. Surg. 27:1997;226-233.
15. Mediavilla M.D., Cos S., Sanchez-Barcelo E.J. Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci. 65:1999;415-420.
16. Castaneda F., Kinne R.K. Apoptosis induced in HepG2 cells by short exposure to millimolar concentrations of ethanol involves the Fas-receptor pathway. J. Cancer Res. Clin. Oncol. 127:2001;418-424.
17. Oh S.H., Lee B.H. Induction of apoptosis in human hepatoblastoma cells by tetrandrine via caspase-dependent Bid cleavage and cytochrome c release. Biochem. Pharmacol. 66:2003;725-731.
18. May P., May E. Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene. 18:1999;7621-7636.
19. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
20. Jiang S., Song M.J., Shin E.C., Lee M.O., Kim S.J., Park J.H. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways. Hepatology. 29:1999;101-110.
21. Lee S.H., Shin M.S., Lee H.S., Bae J.H., Lee H.K., Kim H.S., Kim S.Y., Jang J.J., Joo M., Kang Y.K., Park W.S., Park J.Y., Oh R.R., Han S.Y., Lee J.H., Kim S.H., Lee J.Y., Yoo N.J. Expression of Fas and Fas-related molecules in human hepatocellular carcinoma. Hum. Pathol. 32:2001;250-256.
22. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
23. Kayagaki N., Kawasaki A., Ebata T., Ohmoto H., Ikeda S., Inoue S., Yoshino K., Okumura K., Yagita H. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182:1995;1777-1783.
24. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1998;1205-1213.
25. Antonsson B., Martinou J.C. The Bcl-2 protein family. Exp. Cell Res. 256:2000;50-57.